GlycoMimetics Company Profile (NASDAQ:GLYC)

About GlycoMimetics (NASDAQ:GLYC)

GlycoMimetics logoGlycoMimetics, Inc. is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate, GMI-1070 (Rivipansel), for the treatment of vaso-occlusive crisis (VOC), a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease. The Company is developing GMI-1271, a specific E-selectin inhibitor, to be used in combination with chemotherapy to treat patients with acute myeloid leukemia (AML), multiple myeloma (MM) and other hematologic cancers. The Company has an additional drug candidate, GMI-1359, that targets both E-selectin and a chemokine receptor, CXCR4. The Company is also advancing other preclinical-stage programs, which include small-molecule glycomimetic compounds that inhibit the proteins galectin-3 and galectin-9.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:GLYC
  • CUSIP: N/A
  • Web:
  • Market Cap: $271.29 million
  • Outstanding Shares: 24,640,000
Average Prices:
  • 50 Day Moving Avg: $4.92
  • 200 Day Moving Avg: $5.85
  • 52 Week Range: $3.82 - $14.64
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -19.32
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $18,500.00
  • Price / Sales: 14,664.13
  • Book Value: $1.34 per share
  • Price / Book: 8.22
  • EBIDTA: ($32,110,000.00)
  • Return on Equity: -78.05%
  • Return on Assets: -67.09%
  • Current Ratio: 8.60%
  • Quick Ratio: 8.60%
  • Average Volume: 1.23 million shs.
  • Beta: 2.97
  • Short Ratio: 13.14

Frequently Asked Questions for GlycoMimetics (NASDAQ:GLYC)

What is GlycoMimetics' stock symbol?

GlycoMimetics trades on the NASDAQ under the ticker symbol "GLYC."

How were GlycoMimetics' earnings last quarter?

GlycoMimetics Inc (NASDAQ:GLYC) issued its quarterly earnings results on Monday, May, 8th. The company reported ($0.34) EPS for the quarter, beating analysts' consensus estimates of ($0.37) by $0.03. View GlycoMimetics' Earnings History.

Where is GlycoMimetics' stock going? Where will GlycoMimetics' stock price be in 2017?

5 equities research analysts have issued 1 year target prices for GlycoMimetics' shares. Their predictions range from $12.00 to $16.00. On average, they anticipate GlycoMimetics' stock price to reach $14.33 in the next twelve months. View Analyst Ratings for GlycoMimetics.

What are analysts saying about GlycoMimetics stock?

Here are some recent quotes from research analysts about GlycoMimetics stock:

  • 1. According to Zacks Investment Research, "GlycoMimetics, Inc. is a biotechnology company. The company focused on the discovery and development of novel glycomimetic drugs to address diseases in which carbohydrate biology plays a key role. It product pipeline includes GMI-170, GMI-1271, E-selectin and CXCR4 antagonist, GMI-1051 and GMI-1070 at different clinical phases. GlycoMimetics, Inc. is based in Gaithersburg, United States. " (5/11/2017)
  • 2. Cowen and Company analysts commented, "GLYC’s GMI-1271, an E-selectin antagonist, in a Ph1/2 AML trial, has generated very." (5/9/2017)

Are investors shorting GlycoMimetics?

GlycoMimetics saw a increase in short interest in the month of April. As of April 28th, there was short interest totalling 722,313 shares, an increase of 24.4% from the April 13th total of 580,636 shares. Based on an average daily trading volume, of 45,121 shares, the days-to-cover ratio is presently 16.0 days.

Who are some of GlycoMimetics' key competitors?

Who owns GlycoMimetics stock?

GlycoMimetics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include NEA Management Company LLC (36.80%), Wellington Management Group LLP (13.79%), Sphera Funds Management LTD. (3.33%), Vanguard Group Inc. (1.86%), Candriam Luxembourg S.C.A. (0.69%) and Geode Capital Management LLC (0.41%). Company insiders that own GlycoMimetics stock include Daniel M Junius, Helen M Thackray and Mark Alan Goldberg. View Institutional Ownership Trends for GlycoMimetics.

Who sold GlycoMimetics stock? Who is selling GlycoMimetics stock?

GlycoMimetics' stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, United Services Automobile Association, TIAA CREF Investment Management LLC and Geode Capital Management LLC. View Insider Buying and Selling for GlycoMimetics.

Who bought GlycoMimetics stock? Who is buying GlycoMimetics stock?

GlycoMimetics' stock was bought by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Sphera Funds Management LTD. and Vanguard Group Inc.. Company insiders that have bought GlycoMimetics stock in the last two years include Daniel M Junius and Mark Alan Goldberg. View Insider Buying and Selling for GlycoMimetics.

How do I buy GlycoMimetics stock?

Shares of GlycoMimetics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of GlycoMimetics stock cost?

One share of GlycoMimetics stock can currently be purchased for approximately $11.01.

Analyst Ratings

Consensus Ratings for GlycoMimetics (NASDAQ:GLYC) (?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $14.33 (30.18% upside)

Analysts' Ratings History for GlycoMimetics (NASDAQ:GLYC)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/19/2017Canaccord GenuityReiterated RatingBuy$12.00HighView Rating Details
5/9/2017Cowen and CompanyReiterated RatingBuyLowView Rating Details
11/30/2016SunTrust Banks, Inc.Reiterated RatingBuyN/AView Rating Details
8/5/2016Jefferies Group LLCReiterated RatingBuyN/AView Rating Details
8/5/2016Stifel NicolausBoost Price TargetBuy$13.00 -> $15.00N/AView Rating Details
(Data available from 5/22/2015 forward)


Earnings History for GlycoMimetics (NASDAQ:GLYC)
Earnings by Quarter for GlycoMimetics (NASDAQ:GLYC)
Earnings History by Quarter for GlycoMimetics (NASDAQ:GLYC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2017Q1 2017($0.37)($0.34)ViewN/AView Earnings Details
3/1/2017Q4 2016($0.35)($0.36)$4.50 millionViewN/AView Earnings Details
11/4/2016Q216($0.44)($0.34)$0.02 millionViewN/AView Earnings Details
5/4/2016Q116($0.47)($0.40)ViewN/AView Earnings Details
2/29/2016Q4($0.38)($0.47)$35.00 millionViewN/AView Earnings Details
11/12/2015Q3($0.40)($0.38)$2.10 millionViewN/AView Earnings Details
8/6/2015Q2 2015($0.40)$0.51$20.04 millionViewN/AView Earnings Details
3/16/2015Q4 2014($0.22)($0.39)ViewN/AView Earnings Details
10/31/2014Q314$0.21($0.35)$10.00 millionViewN/AView Earnings Details
7/31/2014Q2 2014$0.24$0.39$9.08 million$15.03 millionViewN/AView Earnings Details
5/8/2014Q114($0.28)($0.30)ViewN/AView Earnings Details
3/31/2014($2.17)($2.80)$9.65 million$0.08 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for GlycoMimetics (NASDAQ:GLYC)
2017 EPS Consensus Estimate: ($1.46)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.38)($0.37)($0.38)
Q2 20172($0.40)($0.30)($0.35)
Q3 20172($0.43)($0.30)($0.37)
Q4 20172($0.44)($0.30)($0.37)
(Data provided by Zacks Investment Research)


Dividend History for GlycoMimetics (NASDAQ:GLYC)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for GlycoMimetics (NASDAQ:GLYC)
Insider Ownership Percentage: 52.50%
Institutional Ownership Percentage: 79.90%
Insider Trades by Quarter for GlycoMimetics (NASDAQ:GLYC)
Institutional Ownership by Quarter for GlycoMimetics (NASDAQ:GLYC)
Insider Trades by Quarter for GlycoMimetics (NASDAQ:GLYC)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/19/2017Helen M ThackraySVPSell2,000$12.14$24,280.00View SEC Filing  
12/20/2016Daniel M. JuniusDirectorBuy5,000$6.01$30,050.00View SEC Filing  
10/3/2016Helen M ThackrayVPSell4,000$7.00$28,000.00View SEC Filing  
7/20/2016Helen M ThackrayVPSell2,000$8.00$16,000.00View SEC Filing  
7/6/2016Helen M ThackrayCMOSell22,000$7.00$154,000.00View SEC Filing  
3/4/2016Mark Alan GoldbergDirectorBuy10,397$4.77$49,593.69View SEC Filing  
12/22/2014Michael A HenosDirectorSell21,257$8.52$181,109.64View SEC Filing  
12/17/2014Michael A HenosDirectorSell6,725$8.97$60,323.25View SEC Filing  
12/15/2014Michael A HenosDirectorSell1,604$8.98$14,403.92View SEC Filing  
6/13/2014Michael A HenosDirectorBuy11,000$6.39$70,290.00View SEC Filing  
1/15/2014Enterprise Associates 13 L NewMajor ShareholderBuy512,500$8.00$4,100,000.00View SEC Filing  
1/15/2014M James BarrettDirectorBuy1,000,000$8.00$8,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for GlycoMimetics (NASDAQ:GLYC)
Latest Headlines for GlycoMimetics (NASDAQ:GLYC)
DateHeadline logoGlycoMimetics Inc (GLYC) SVP Helen M. Thackray Sells 2,000 Shares - May 22 at 10:28 PM logoGlycoMimetics Inc (GLYC) Given Average Rating of "Buy" by Analysts - May 22 at 6:20 PM logoGlycoMimetics Announces Proposed Public Offering of Common Stock - May 22 at 5:02 PM logoHere's Why GlycoMimetics (GLYC) Stock Skyrocketed Over 100% Today - May 19 at 10:16 PM logoGlycoMimetics Inc (GLYC) Stock Rating Reaffirmed by Canaccord Genuity - May 19 at 9:36 PM logoWhy GlycoMimetics Is Ripping 19% Higher Today - May 19 at 5:15 PM logoETFs with exposure to GlycoMimetics, Inc. : May 19, 2017 - May 19 at 5:15 PM logoGlycoMimetics Inc. (GLYC) Soared To A New High On FDA Breakthrough Designation - May 19 at 8:36 AM logoCompany Spotlight: GlycoMimetics - May 19 at 8:36 AM logoDon't Trust the Bounce Yet - May 19 at 8:36 AM logoHere's Why GlycoMimetics (GLYC) Stock Skyrocketed Over 100% Today - May 19 at 8:36 AM logoToday's Research Reports on Stocks to Watch: GlycoMimetics and Endologix - May 19 at 8:36 AM logoGlycoMimetics (GLYC) Announces FDA Breathrough Therapy Designation for GMI-1271, Adult Relapsed/Refractory Acute Myeloid Leukemia - May 18 at 9:51 AM logoSNDX Rises On Entinostat Data, Kalydeco Gets FDA Nod, Concert Fails To Enthrall - May 18 at 9:51 AM logoBRIEF-Glycomimetics reports supportive biomarker data from early-stage trial of GMI-1271 - May 18 at 9:51 AM logoGlycoMimetics Announces High Overall Response Rates, Low Induction Mortality, Promising Initial Survival Outcomes, and Supportive Biomarker Data from Phase 1/2 Trial of GMI ... - May 18 at 9:51 AM logoGlycoMimetics Announces High Overall Response Rates, Low Induction Mortality, Promising Initial Survival Outcomes, and Supportive Biomarker Data from Phase 1/2 Trial of GMI-1271 in AML - May 18 at 9:51 AM logoGlycoMimetics Inc. (GLYC) Is Surging After FDA Breakthrough Designation - May 17 at 10:30 PM logoGlycoMimetics’ GMI-1271 Receives FDA Breakthrough Therapy Designation for Adult Relapsed/Refractory Acute Myeloid Leukemia - May 17 at 5:28 PM logoGlycoMimetics Inc (GLYC) Short Interest Up 24.4% in April - May 13 at 2:38 PM logoGlycoMimetics Inc (GLYC) Lowered to "Hold" at Zacks Investment Research - May 11 at 10:52 PM logoGlycoMimetics Inc (GLYC) Rating Reiterated by Cowen and Company - May 9 at 10:28 PM logoGlycoMimetics Inc (GLYC) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPS - May 9 at 12:52 PM logoGlycoMimetics Reports Program Updates and First Quarter 2017 Results - May 8 at 5:13 PM logoGlycoMimetics reports 1Q loss - May 8 at 5:13 PM logoGlycoMimetics (GLYC) Earning Positive Press Coverage, Analysis Finds - May 4 at 8:56 AM logoGlycoMimetics Inc (GLYC) Upgraded to "Buy" at Zacks Investment Research - May 3 at 1:10 AM logoGlycoMimetics Announces Publication of Preclinical Data Showing Role of E-selectin Ligands in Multiple Myeloma - May 2 at 1:49 PM logoGlycoMimetics Inc (GLYC) Expected to Announce Earnings of -$0.38 Per Share - May 2 at 12:06 AM logoGlycoMimetics (GLYC) Earns News Sentiment Score of -0.22 - May 1 at 11:21 AM logoGlycoMimetics (GLYC) Receiving Somewhat Negative Press Coverage, Report Shows - April 26 at 11:14 AM logoGlycoMimetics Inc (GLYC) Given Average Recommendation of "Buy" by Brokerages - April 25 at 5:50 PM logoGlycoMimetics (GLYC) Receiving Positive Press Coverage, Report Shows - April 20 at 4:23 PM logoGlycoMimetics to Present New AML Clinical Data at ASCO 2017 Annual Meeting - April 20 at 12:04 PM logoZacks: Brokerages Expect GlycoMimetics Inc (GLYC) to Announce -$0.38 EPS - April 10 at 8:30 PM logoETFs with exposure to GlycoMimetics, Inc. : April 5, 2017 - April 7 at 10:02 AM logoGlycoMimetics Inc (GLYC) Given Average Rating of "Buy" by Brokerages - March 31 at 2:06 PM logoGLYCOMIMETICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure - March 13 at 5:26 PM logoGlycoMimetics Completes Enrollment of Newly Diagnosed AML Patient Cohort in Phase 2 Clinical Trial of GMI-1271 - March 7 at 11:24 AM logoGlycoMimetics to Present New Preclinical Data in Multiple Myeloma at AACR Annual Meeting 2017 - March 1 at 10:09 PM logoGLYCOMIMETICS INC Files SEC form 10-K, Annual Report - March 1 at 5:08 PM logoBRIEF-Glycomimetics Q4 loss per share $0.36 - March 1 at 12:13 PM logoGlycoMimetics to Present at Cowen 37th Annual Health Care Conference - February 28 at 5:38 PM logoForm SC 13G/A GLYCOMIMETICS INC Filed by: FRANKLIN RESOURCES INC - February 8 at 6:02 PM logo3 Greater Washington biotech execs sign industry letter opposing the Trump travel ban - February 8 at 6:02 PM logoBidding War For Galectin Inhibitors May Heat Up With GTCBio Conference - February 6 at 5:31 PM logoGreater Washington's fastest-growing company forced to lower earnings, income for two years - January 24 at 6:08 PM logo10:04 am GlycoMimetics announces results of its Phase 1/2 clinical trial on GMI-1271 continue to show 'high rates of remission' and 'favorable' tolerability among study participants with acute myeloid leukemia; data shared at the 58yh Ameri - December 5 at 6:02 PM logoGlycoMimetics (GLYC) Announces Positive Update on GMI-1271 Phase 1/2 in AML; All Response Patients Seen with CR Rates - December 5 at 11:21 AM logoGlycoMimetics' GMI-1271 Continues to Yield High Remission Rates, Favorable Tolerability in Two Phase 2 Arms of Ongoing Phase 1/2 Clinical Trial for AML - December 5 at 11:21 AM


GlycoMimetics (GLYC) Chart for Monday, May, 22, 2017

This page was last updated on 5/22/2017 by Staff